HLN Haleon plc
Trend channel, buy level and 3-month target. Information only, not financial advice.
At the channel floor · 9-month channel falling
Price is on the lower line, where it has held before.
- 9-month channel read from
- US$8.66 – US$10.11 · falling, −10% a year
- 12-month channel
- US$8.66 – US$10.18 · going sideways, −2% a year
- Price in channel
- 0.2% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$10.11
- Turns bearish below
- US$8.66
What broke this trend
- The fall
- -23% from US$11.142 June 2025 → 29 Oct 2026
- Whose problem it was
- This company0 of 1 Drug Manufacturers - Specialty & Generic peers fell with it
- Does it resolve?
- Temporary falls like it have resolved on the record
- Regained so far
- 4%of what it lost
- What the record says
- 90% of 1032 comparable falls came back, typically in 63 days measured across every stock we hold history for, its peer group being too small
Fell -23% (2 June 2025 → 29 Oct 2026); regained 4% so far; company-specific.
Price history, with the path projected 3 months forward
Updated 9:23 AM ET (27 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy now
US$8.66
last close · 30 Oct 2026
Our target
US$9.95
by 26 Dec 2026
Projected move
14.9%
gross, before costs
Last close is our buy.
Target: HLN's usual move size.
This move size: reached in 42% of 15 past stretches, typically in 67 days. (0.12% per day)
- Upper line touches
- 3
- Lower line touches
- 3
- Fit confidence
- 67%
- Fitted
- 1 Nov 2026
Company information
About Haleon plc
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Brian James McNamara
- Employees
- 24,535
- Country
- GB
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$37.69B
- Enterprise value
- —
- Beta
- 0.24
- Avg volume
- 13.56M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 8.38-11.28
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.